Q-omics provides the consensus-scored PDE4A profile across patient tissues and cancer cell-line models. PDE4A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PDE4A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PDE4A protein abundance shows 24,086 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, KIRC, and GBM as cancer lineages where PDE4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4A survival associations across molecular data types. PDE4A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4A RNA expression–survival associations across cancer types. High PDE4A expression shows unfavorable associations in UCS, UVM, LUSC and BLCA, but favorable associations in KIRC and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PDE4A RNA expression.
This table summarizes PDE4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PDE4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4A shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRC, HNSC, LIHC and CHOL. The KIRC box plot shows higher PDE4A RNA expression in tumor versus normal tissue (log2 FC = +0.862, t-test p < 0.001).
This table shows molecular features associated with PDE4A in patient tissues and cancer cell lines. In patient samples, PDE4A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
